Journal of Clinical Oncology
Articles in this Issue
Association of immune checkpoint inhibitors with increased pancreatitis risk in gastrointestinal cancers: A propensity-matched real-world analysis.
e16498 Background: Immune checkpoint inhibitors (ICIs) are widely used in gastrointestinal (GI) malignancies but are assoc...
Early-onset gastrointestinal cancers: Racial disparities in stage and survival from large-scale community oncology data.
1653 Background: Research on early-onset (EO) gastrointestinal (GI) cancers has focused predominantly on colorectal cancer...
Preliminary efficacy and safety of first-line anlotinib plus carboplatin/paclitaxel induction therapy followed by anlotinib maintenance in advanced ovarian cancer: Results from the ALTER-GO-010 phase II multicenter trial.
5576 Background: Several studies have shown that antiangiogenic drugs combined with chemotherapy as first-line treatment,...
A novel syngeneic immunocompetent mouse model of GBC to reveal CXCL5-mediated early tumor progression and demonstrate chemotherapeutic sensitivity.
e16264 Background: Gallbladder cancer (GBC) is a highly lethal malignancy with a poor prognosis. Research progress has bee...
Comparative pharmacovigilance analysis of adverse events associated with zanidatamab versus trastuzumab using the FDA Adverse Event Reporting System.
e23383 Background: Zanidatamab, a bispecific antiHER2 antibody, has demonstrated promising activity in HER2 expressing mal...
Liposomal irinotecan combined with 5-FU/LV and bevacizumab as second-line therapy for metastatic colorectal cancer: A multicenter, single-arm phase II study (IRIS).
e15569 Background: For patients with metastatic colorectal cancer (mCRC) who progress after first-line oxaliplatin-based t...
A phase 2 clinical study of nimotuzumab plus S-1 and concurrent radiotherapy in 75 years and older patients with esophageal squamous cell carcinoma.
4027 Background: Concurrent chemoradiotherapy is the standard treatment method for inoperable and locally advanced esophag...
Cardiac safety of aldoxorubicin compared to doxorubicin: Integrated results from two randomized studies in advanced soft tissue sarcoma.
11565 Background: Doxorubicin clinical benefit is limited by cumulative, irreversible cardiotoxicity that restricts dosing...
NRG-HN015: A phase II randomized trial of neoadjuvant chemotherapy or chemo-immunotherapy in patients with recurrent/persistent PD-L1–positive squamous cell carcinoma of the head and neck undergoing salvage surgery.
TPS6128 Background: Treatment for locoregionally recurrent squamous cell carcinoma of the head and neck (SCCHN) remains a...
MATCHES-NOVEL: A randomized controlled trial in progress of hospital-at-home (HaH) versus inpatient hospitalization for post tarlatamab monitoring.
TPS1683 Background: Tarlatamab is a bispecific T-cell engager (BiTE) therapy approved for the treatment of extensive-stage...
Role of CAR-T cell therapy in prostate cancer: A systematic review and meta-analysis.
e17075 Background: Chimeric antigen receptor (CAR) T-cell therapies targeting prostate-associated antigens, such as prosta...
Oral cavity and oropharyngeal cancer incidence: 5-year survival vs. air pollution levels across New York State.
e18111 Background: Smoking prevalence in the US has decreased but incidence of oral cavity and oropharyngeal cancers (OCC/...
Impact of clinical and treatment characteristics on fear of cancer recurrence and quality of life in survivors of early-stage breast cancer.
e12684 Background: Fear of cancer recurrence (FCR) is one of the most frequent concerns among breast cancer survivors and...
Where climate hits hardest: Geographic patterns in climate education across 266 U.S. oncology fellowship programs.
e23155 Background: Climate change disproportionately affects cancer patients through care disruptions and treatment delays...
Paclitaxel, carboplatin, and durvalumab in extensive stage small-cell lung cancer (ES-SCLC; IFCT-2203 TAXIO phase II trial): Can we improve the chemotherapy (CT) immunotherapy combination in SCLC?
8091 Background: Etoposide+platinum-based CT and anti-PD-L1 is the backbone of ES-SCLC treatment. We hypothesize a deleter...
Organ preservation and local excision for rectal cancer: Long-term oncologic outcomes.
3655 Background: Organ preservation is a desired outcome for rectal cancer patients after neoadjuvant chemoradiotherapy. I...
Trends in cancer incidence and mortality of children, adolescents, and young adults in Hong Kong, 2003-2023: Comparison with East Asia, US, UK, and Australia.
e22614 Background: Although survival of cancers in childhood, adolescence and young adulthood (CAYA) has improved globally...
Plasma exchange in myeloma-associated acute kidney injury: A multicenter propensity-matched cohort study.
7575 Background: Acute kidney injury (AKI) in newly diagnosed multiple myeloma (MM) is frequently driven by light chain ca...
Trends in mortality related to anal carcinoma in the United States, 1999–2023: A population-based analysis using CDC WONDER.
e15500 Background: Anal carcinoma is an uncommon but increasingly recognized malignancy with established associati...
Burden of coronary heart disease and hepatocellular carcinoma mortality among U.S. adults: A 25-year analysis.
e16492 Background: Coronary heart disease (CHD) and hepatocellular carcinoma (HCC) are leading causes of morbidity and mor...
Extrachromosomal DNA as a shaper of aggressive transcriptional states in multiple myeloma.
7555 Background: Extrachromosomal DNA (ecDNA) is increasingly recognized as a key driver of oncogene amplification, intrat...
Final results of a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin, and pazopanib: 2ND-STEP study, JCOG1802.
11508 Background: The optimal second-line treatment for advanced soft tissue sarcomas (STS) after doxorubicin therapy rema...
Molecular profiling of endometrial cancer subsets: <i>Pole</i> hotspot mutations, mismatch repair status, microsatellite instability, TP53 mutation.
e17642 Background: Molecular characterization of endometrial cancer (EC) is essential for therapeutic stratification and p...
Evaluation of a tissue-free genome-wide methylome enrichment assay for detecting molecular residual disease (MRD) in patients with head and neck squamous cell carcinoma (HNSCC).
6084 Background: Squamous cell carcinomas comprise ~90% of head and neck cancers (HNCs). Although ~80% of patients with HN...
A late-phase randomized open-label multi-cohort trial to evaluate immune-related adverse events with different standard-of-care dosing strategies of standard-of-care immunotherapies: ImmuRAd trial.
TPS12172 Background: Programmed cell death-1 (PD-1) inhibitors, such as nivolumab and pembrolizumab, are widely used in tr...